US20180264463A1 - Apparatus and method for separating and analyzing blood - Google Patents
Apparatus and method for separating and analyzing blood Download PDFInfo
- Publication number
- US20180264463A1 US20180264463A1 US15/989,068 US201815989068A US2018264463A1 US 20180264463 A1 US20180264463 A1 US 20180264463A1 US 201815989068 A US201815989068 A US 201815989068A US 2018264463 A1 US2018264463 A1 US 2018264463A1
- Authority
- US
- United States
- Prior art keywords
- reagent
- blood
- blood plasma
- marker
- collecting chamber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/16—Reagents, handling or storing thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0663—Whole sensors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0478—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure pistons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
Definitions
- the invention relates to an apparatus for separating and analyzing blood.
- deviations from a normal blood picture can be determined, from which, for instance, a pathological defect or a risk factor can be determined, at least it can be indicated that further examination thereof is advisable or necessary.
- a healthy blood picture may also be determined.
- an apparatus with which an amount of blood can be received in a chamber, the blood being diluted and then at least partly being pressed through a filter.
- the filter is chosen such that at least the blood plasma from the blood can pass this filter and is collected in a collecting space, while at least the red blood cells from the blood cannot pass the filter and remain behind the chamber. Then a seal is provided in the passage between this chamber and the collecting space, so that the plasma cannot flow back.
- the apparatus is subsequently sent to a laboratory in order to carry out an analysis of the plasma.
- it is particularly important that the separation between the plasma and the red blood cells is maintained, because otherwise, for instance, coagulation could occur, which makes the blood unusable for various tests afterwards.
- the analysis of the blood plasma is done by, for instance, spectral analysis.
- U.S. 2004/0133146 A1 describes an apparatus, where blood is sucked up with the aid of a thin tube, which blood is then supplied into a chamber, after which it is pressed against a filter with the aid of a piston, such that at least the blood plasma is forced through the filter and at least the red blood cells remain behind in the chamber.
- the separated blood plasma can then be examined, for instance with spectral analysis.
- these apparatuses Compared to whole blood analysis, these apparatuses have the advantage that the blood does not need to be centrifuged. Thus, much less blood needs to be tapped and tests can be carried out more quickly.
- GB 2 392 854 describes a filtration apparatus provided with a first chamber and a second chamber, mutually separated by a filter membrane.
- this apparatus is described for the separation of blood into plasma and other blood components.
- the second chamber is provided with a hollow plunger with the filter element at the leading end.
- beads comprising reagent for a substance in the blood plasma.
- the plunger is pressed into whole blood in the first chamber, so that blood plasma is forced through the filter into the second chamber.
- the beads dissolve in the blood plasma and react with the substance to be detected, so that a color change occurs as an indication of the presence of that substance. This test takes at least ten minutes.
- EP 1 221 340 describes a universal testing apparatus in which different reagents can be provided, between or on filters. All kinds of liquids to be analyzed, such as whole blood, serum, foodstuffs and the like can be led along them for obtaining reactions. For use of serum, it is described that a gel with reagent can be provided between the filters. The filters then serve to clean the serum. Serum is separated from whole blood outside the apparatus and is introduced into the apparatus as such.
- EP 1152 241 describes an apparatus, in a series of embodiments, where at least three chambers are used for sequentially separating parts of whole blood, in order to collect blood plasma in a last chamber. Separation of different fractions of the blood is at least partly brought about by centrifugation.
- U.S. Pat. No. 3,481,477 describes an apparatus for separating whole blood into serum and solid parts.
- a piston is provided in a tube, with the end of the piston being provided with a filter.
- Filter tablets can be provided for forming the filter.
- a thin capillary tube is connected to the filter.
- blood is introduced into the tube, after which the piston with the filter is pressed against the blood.
- Serum is forced by the filter tablets and is discharged via the capillary tube to a test tube or a reservoir formed in the inside of the piston.
- the filter tablets can contain a reagent for filtering components from the serum.
- Such an apparatus offers the advantage that it can be carried out by a patient himself or herself or in his or her presence, so that the time for obtaining the test results can be reduced considerably.
- tests also still require a few minutes or more, which is in many cases undesired.
- these tests have the drawback that they are very sensitive to, for instance, pollution from outside, since the apparatus is open, while, in addition, the degree of separation and consequently the amount of blood plasma obtained cannot he determined sufficiently accurately.
- this drawback is increased further because it is unclear bow much blood plasma ends up on which layer of the filter.
- the invention contemplates providing an apparatus and/or method for analyzing blood.
- the invention particularly contemplates providing a method and/or apparatus for relatively quickly separating at least blood plasma and red blood cells from whole blood and then analyzing at least the blood plasma.
- a further object of the invention is providing a method and/or apparatus with which a user can carry out blood tests independently and relatively quickly.
- the invention further contemplates providing an apparatus and/or method which enables separation and analysis of blood, where indications can be given of threshold values of one or more blood-related factors.
- an apparatus is characterized in that at least separating means for separating blood plasma and red blood cells are included, which separating means comprise pressure means for pressing at least a part of the blood through a filter, while at least first collecting means are provided for collecting separated blood plasma and at least one reagent which is provided in these first collection means or can be introduced therein for reaction with substances or organisms present in this blood plasma.
- the advantage is achieved that at least blood plasma is separated under pressure from at least red blood cells, so that virtually instantaneously, the desired separation of blood plasma and red blood cells is obtained.
- at least the blood plasma is collected in collecting means in which the blood plasma directly comes or can be brought into contact with at least one reagent, so that, within a particularly short time, it can be determined whether a particular component in the blood of the respective is present, at least exceeds a particular value or limit.
- reagents which allow visually determination of whether or not a respective reaction occurs, for instance by color change, structural change such as coagulation, dissolving, or the like.
- the blood plasma is preferably collected in the first collecting means, designed as a space, separated from the environment, so that no pollution or leaking out of blood plasma can occur.
- a known amount of diluent liquid is provided, in particular in above-mentioned chamber, while, in addition, a known amount of blood is introduced, so that the degree of dilution of the blood is always accurately known.
- accurate test results can be achieved quickly and simply.
- the at least one reagent is provided in the first collecting means, in particular on a wall part thereof.
- this wall part is at least partly transparent so that change of, for instance, color or structure of the reagent is clearly visible from the outside of the apparatus, at least of the first collecting means, without these needing to be opened.
- the at least one reagent is provided on an element or in an element which is or can be inserted into the first collecting means. This offers at least the advantage that the apparatus can have a substantially universal design, while, each time, a suitable reagent can be chosen, depending on the test to be carried out.
- the reagent is chosen and/or dosed such that end point values can be determined, so that it can at least be seen whether a particular factor in the blood is above or below a preselected value.
- the apparatus is provided with a piston with which the blood, at least the blood plasma, can be pressed through a filter, while the first collecting means are preferably provided in the piston.
- the at least one reagent may then be provided on or in the piston.
- each time one reagent can be used, but combinations of reagents may also be provided, for simultaneously carrying out a series of tests.
- combinations of reagents may also be provided, for simultaneously carrying out a series of tests.
- rings, surfaces or the like of different reagents may be provided.
- a reagent may also be provided in a different aggregation condition, for instance liquid or in the form of a solid.
- the at least one reagent is provided in or on a separate holder, while the apparatus for separating the blood is provided with a pouring opening, particularly near the first collecting means, so that, after the blood plasma has been separated from the red blood cells, it can be poured into or on this holder, at least this at least one reagent.
- the at least one reagent is preferably chosen from the group of reagents which only indicate presence of a substance or organism in the blood plasma and not a value for the concentration or the like.
- the at least one reagent is therefore essentially binary: reaction of the reagent indicates, for instance by color change, coagulation or other transformation of the reagent, the blood plasma or a reaction between them, whether a particular threshold value is exceeded or not.
- reagents can be used which can indicate the presence of antigens, for instance a degree in which they are to be present or that a limit value is exceeded, for instance antigens with which the presence of tumors can be demonstrated or at least can be shown to be plausible.
- reagents can be used with which the presence of, for instance, vitamins can he determined.
- Reagents can further be used with which, in case of exceeding or, conversely, falling short of a limit value, it can be indicated whether the exceeding is harmful to a patient.
- Such a reagent can advantageously be combined with a reagent which indicates exceeding or falling short of this limit value.
- reagents can be used with which a therapeutic or non-therapeutic blood level can be determined, for instance of a medicine or toxic, for instance a medicine depending, for an optimal effect, on an optimal blood level or on a blood level which is not to be exceeded due to, for instance, undesired side effects. Combinations of reagents as mentioned may also be used. These reagents and uses are of course only mentioned by way of illustration and should not be taken as being limitative in any way.
- FIG. 1 shows, in cross-sectional view, prior to use. an apparatus according to the invention, in a first embodiment
- FIG. 2 shows, in partly retracted condition, an apparatus according to FIG. 1 ;
- FIG. 3 shows, in wholly retracted condition, an apparatus according to FIGS. 1 and 2 ;
- FIGS. 4A and B show, in partly cross-sectional side elevational view, an alternative embodiment of an apparatus according to the invention, in a starting position and an end position, respectively;
- FIG. 4C schematically shows, in cross-sectional side elevational view, a filter for an apparatus according to FIG. 4 ;
- FIG. 5 schematically shows an insertion element for use with an apparatus according to the invention.
- FIG. 6 shows, in side elevational view, a trunk of an apparatus according to FIG. 1 , in an alternative embodiment.
- FIG. 1 shows, in partly cross-sectional side elevational view, an apparatus 1 according to the invention, in a first embodiment, in two parts.
- a first part 2 is shown, formed by a transparent plastic casing 3 , closed on a bottom side by a sharply tapering bottom 4 and open on the opposite side 5 .
- the open side 5 is provided with a neck 6 with external screw thread 7 on which a cap 8 is screwed.
- the cap 8 clamps a gasket 9 on the neck 6 , so that the inner space or chamber 10 within the casing 3 is closed off.
- a diluent liquid 11 is received, in a predetermined amount.
- FIG. 1 shows, on the right side, second part 20 in the form of a piston part 12 , comprising an at least partly transparent tubular part 13 with an open bottom end 14 and an opposite open top end 15 , surrounded by a collar 16 .
- a flexible ring 17 is provided with an outer diameter D b which matches the inner diameter D i of the casing 3 of the first part 2 in a manner to be described in more detail.
- a trunk 18 is inserted, which has an outer diameter D 1 which is smaller than the inner diameter D 2 of the tubular part 13 .
- a collar part 19 is provided which, on the top side, connects to an apron 21 extending outwards and is provided with an internal screw thread 22 which fits on the external screw thread 7 of the first part 2 .
- the collar part sealingly fits into the top end 15 , while the apron can abut the outside of the collar 16 .
- the trunk 18 and the collar part 19 have such a length that, in the position shown in FIG. 1 , the bottom end 24 of the trunk 18 is at some distance from the bottom end 14 within the tubular part 13 .
- a stop 25 is placed, which will further be explained.
- a filter 26 is provided through which at least blood plasma can pass, but through which red blood cells cannot pass, at least with some dilution of the blood. Examples of filters and dilutions to be used are given in U.S. 2003/1075167 A1, which are not to be taken as being limitative in any way.
- FIG. 2 shows the second part 20 in a condition where it is partly retracted into the first part 2 , where a drop of blood with known volume is 15 mixed into the diluent liquid.
- the filter 26 lies on the diluted blood and the ring 17 seals against the inside of the casing 3 .
- the chamber 10 is closed.
- the second part 20 can be pressed downwards further, in the direction of the bottom 4 .
- the filter 26 is forcefully pressed against the diluted blood, so that blood plasma is pressed upwards through the filter 26 while the red blood cells are stopped and remain behind in the chamber 10 .
- first collecting means 27 are formed, in the form of a ring chamber, in which the blood plasma is collected.
- FIG. 3 shows, in cross-sectional side elevational view, an apparatus 1 according to the invention, where the second part 10 is completely pressed into the first part 2 , so far that the internal screw thread 22 is screwed on the external screw thread 7 and the stop 25 closes off the open end of the tubular part 13 above the filter 26 , so that the blood plasma 28 is prevented from flowing back from the first collecting means 27 .
- At least one surface 29 is provided which contains a reagent 30 for at least one element which is present, at least can be present, in the blood plasma 28 .
- the reagent 30 is provided as a ring-shaped surface, so that it is visible from the outside from all sides of the assembled apparatus 1 . This allows reaction of the reagent 30 with above-mentioned element to be observed clearly, for instance due to color change, structural change, clotting, dissolving, or the like, if this element is present to a particular degree in the blood plasma.
- the reagent 30 or reagents can be chosen on the basis of the elements whose presence, concentration, level or the like needs to be determined. If desired, two or more surfaces 29 , 29 A, 29 B, 29 . . . may be provided, with the same reagent but preferably with different reagents 30 A, 30 B, 30 . . .
- the reagent is provided on the trunk 18 in the form of a ring-shaped surface 29 .
- the trunk 18 can be chosen, for instance from a set of trunks 18 with different reagents, depending on the desired elements to be determined. Incidentally, this may of course also be achieved with different tubular elements 13 with different reagents.
- an apparatus according to the invention may be supplied with a series of insertion elements such as (hollows) rods 31 , rings 32 or the like as schematically shown in FIG. 6 , where the different insertion elements carry different reagents 30 , 30 A, 30 . . .
- a suitable reagent or combination of reagents can be provided in the tubular element 13 .
- Ring-shaped elements can then, for instance, be slid around the trunk 18 for forming a trunk 18 as shown in FIG. 6 .
- Rods or the like may, for instance be placed in openings or slots in the trunk 18 or in a jacket or chamber enclosing the or each trunk, such as a space 27 or a tube 13 , for instance loosely inserted.
- FIG. 5 schematically shows. in perspective view, an alternative embodiment of an insertion element 32 for use in an apparatus according to FIGS. 1-3 .
- This insertion element 32 is substantially formed by a hollow cylindrical body 50 , which comprises a ring-shaped portion 52 at a first end 51 , from which a number of fingers 53 extend, in the direction of an opposite second end 54 .
- the fingers 53 Near this second end 54 , the fingers 53 have a reduction 55 in that a portion 56 of each finger is offset inwards with respect to an outer surface 57 of above-mentioned body 50 .
- a reagent 30 is provided on the outwardly facing surface 29 of the reduction 55 , on each finger 53 .
- the cylindrical body 50 has an outer diameter D 3 which is approximately equal to the inner diameter D 2 of the body 13 , so that it can be retracted into the body 13 from the top end 15 , preferably with the fingers 53 in the direction of the end 14 .
- the outer surface 57 can then abut the inside of the body 13 , while the surface 29 is kept at a distance therefrom. This allows the reagent 30 , 30 A, 30 . . . to properly come into contact with plasma collected in the space 27 .
- the reagent may also be provided in a different manner, for instance directly on the surface 57 , if it is kept at a distance from the wall of the body 13 , or on an inwardly facing surface of the insertion part 32 , in which case it is advantageous when at least the fingers 53 are at least partly transparent at the height of the reagent 30 .
- reagent or reagents or similar terms are also at least understood to mean antibodies or enzymes, which means that tests can he applied which are based on antibodies or enzymes.
- reagents and other markers may be used, such as for instance antigens, chemical reagents, enzymes, chemical markers and the like.
- Reagents and markers may, for instance, he used for indicating problems with a heart, liver, kidney or other organs, glucose abnormalities such as diabetes, cholesterol abnormalities, abnormalities in one or more hormones, blood values in general and the like, viral or bacterial abnormalities such as influenza, malaria, hepatitis, HIV, inflammations, MS, ME and other indicators, in particular for existing health problems and/or health problems possibly to he expected.
- abnormalities are understood to mean such deviations from values normally expected for a respective person that, for a doctor, these would be or should be a reason to carry out further examinations or to intervene by, for instance, administering medicines, liquids, nutrients or to intervene surgically.
- reagents 30 examples include antibodies for HTLV I and/or II, cystatin C or similar markers for kidney functions or heart functions such as cardiovascular problems, heart infarcts ((myocardial) infarct) and/or heart attack (stroke), monoclonal antibodies, coagulation reagents such as lupus anticoagulant-sensitive or insensitive reagents, PSA antigen, HBS-1, HLA antibodies, HbA(1c) or GlyHb in hemoglobin measurement.
- antibodies for HTLV I and/or II cystatin C or similar markers for kidney functions or heart functions such as cardiovascular problems, heart infarcts ((myocardial) infarct) and/or heart attack (stroke), monoclonal antibodies, coagulation reagents such as lupus anticoagulant-sensitive or insensitive reagents, PSA antigen, HBS-1, HLA antibodies, HbA(1c) or GlyHb in hemoglobin measurement.
- a surface 29 of cholesterol reagent, CHOD-Pap, BoehringerMannheim GmbH is provided as a reagent 30 , which reagent 30 is suitable for demonstrating cholesterol (total cholesterol, HDL or LDL).
- a surface 29 of cholesterol reagent, CHOD-Pap, BoehringerMannheim GmbH is provided as a reagent 30 , which reagent 30 is suitable for demonstrating cholesterol (total cholesterol, HDL or LDL).
- 220 microliters of diluent liquid (buffer) were provided, after which 60 microliters of blood were diluted therein.
- This blood plasma was brought into contact with the reagent by agitation (horizontal rocking), so that the reagent changed color from a neutral color to a characteristic color, in this case red, clearly visible from the outside. It was thus found that the cholesterol level in the blood was higher than a threshold value of 6.5 mmol/l. Control measurements of the whole blood taken via a venous blood sample and tested in laboratory demonstrated that the blood indeed had a value above that threshold value.
- FIGS. 4A and B schematically show an apparatus 1 according to the invention, in an alternative embodiment, the basis of which is described in NL 1016646, which publication is understood to be incorporated herein by reference, at least with regard to the operation for separating plasma from blood.
- This apparatus 1 comprises a hollow cylindrical body 33 in which a first piston 34 is sealingly movable with the aid of a pressure body 35 which, in a first position, rests against an end of the trunk 36 connected with the first piston and, in a second position, for instance rotated with respect to the first position through an angle of about 90 degrees about a longitudinal axis of the body 33 , over the trunk 36 . So, in the first position, the first piston 34 can be pressed in the direction of a bottom end 37 of the body 33 with the aid of the pressure body 35 , up to against a stop 38 .
- a second piston 39 with trunk 46 is provided around the trunk 36 and seals against both the trunk and the inside of the body 33 .
- the second piston 39 is, for instance, a rubber ring.
- a treatment space 40 is enclosed, the volume of which is variable.
- a treatment fluid or other material can be included, such as a buffer 11 , for instance a phosphate buffer, similar to FIGS. 1-3 .
- an inlet opening 42 and an outlet opening 43 are provided in a wall 44 of the body 33 .
- a capillary 44 can be inserted into the inlet opening, so that the contents of the capillary 44 can be sucked into the body, between the two pistons 34 , 39 , in the treatment space 40 , as will be discussed hereinbelow.
- a filter 26 connects, into which and/or through which at least the contents of the treatment space 40 can be forced.
- the pistons 34 , 39 are relatively high in the body 33 and relatively close to each other.
- the inlet opening preferably opens just into the treatment space, which treatment space 40 has a relatively small volume.
- a capillary 44 filled with whole blood 45 as a sample is inserted into the inlet opening 42 .
- the filter may be any suitable filter, for instance a glass fiber filter.
- plasma is separated from the blood, in that the plasma is pressed through the filter, with blood particles such as erythrocytes and leukocytes removed.
- At least one test surface 29 is provided as shown in FIG. 4C , formed by or comprising a reagent 30 , such as for instance mentioned hereinabove.
- a reagent 30 such as for instance mentioned hereinabove.
- the plasma is forced through the filter, it directly and intensively comes into contact with the or each test surface 29 and consequently with the or each reagent 30 , so that the test result can be read out virtually instantaneously.
- An advantage is that it does not need to be provided on an external reagent surface, so that pollution of the plasma and/or the reagent can be prevented.
- the plasma can be collected in the filter 26 , at least the housing 47 thereof, so that pollution and in particular contamination of the environment can be prevented. This is particularly important in use of biological samples such as blood in which pathogenic elements may be present.
- FIG. 4C schematically shows a filter 26 for an apparatus 1 according to FIGS. 4A and B, which filter 26 comprises a housing 47 .
- the housing 47 is at least partly and preferably wholly transparent, such that the filter surface 48 or at least a part thereof on which reagent 30 is provided can be seen without the housing 47 needing to be opened. This prevents pollution of plasma, reagent and/or the environment.
- the housing 47 may, for instance, comprise two housing parts 48 , 49 attached to each other enclosing a filter element 57 as described earlier, for separation of blood plasma and blood corpuscles.
- a chamber 58 is provided in which blood corpuscles remain behind, above the filter element 57 .
- a collecting space 27 is provided in which the separated plasma 28 is collected.
- at least one surface 29 is provided on which or in which a reagent can be included for reaction with the blood plasma.
- This surface 29 may, for instance, be provided on the filter element 57 , on the side thereof facing the collecting space 27 , while it may, for instance, have a porous design, so that intensive contact is obtained between plasma and reagent.
- the surface 29 may also, as shown in FIG.
- the second housing part 49 has a transparent design, at least at the height of the surface 29 , here provided on a block 59 , so that, for instance, discoloration of the block as a result of the reaction between elements of or in the plasma and the or a reagent 30 is visible from outside the housing 47 .
- a housing can be used in which the plasma is at least partly collected, while the housing is at least partly transparent and the or each reagent is provided therein. This offers the advantage of good protection against pollution and/or contamination.
- the apparatus or at least the plasma collected therein can then be used for further tests.
- the apparatus as a whole or the filter and/or the housing may, for instance, be sent to a laboratory, where further tests can be carried out to, for instance, verify a first indication obtained with the or a reagent or to examine it further.
Abstract
An apparatus, comprising at least separating means (1) for separating blood plasma and red blood cells, which separating means (1) comprise pressure means (20) for pressing at least a part of the blood through a filter (26), wherein at least first collecting means (27) are provided for collecting separated blood plasma and at least one reagent is provided in said first collecting means (27) or can be introduced therein for reaction with substances or organisms present in said blood plasma.
Description
- This application is a divisional of U.S. Ser. No. 12/526,394 having an international filing date of Feb. 8, 2008 (now allowed), which is the national phase of PCT application PCT/NL2008/050072 having an international filing date of Feb. 8, 2008, which claims benefit of Dutch patent application No. 1033365 filed Feb. 9, 2007. The contents of the above patent applications are incorporated by reference herein in their entirety.
- The invention relates to an apparatus for separating and analyzing blood.
- By blood analysis, deviations from a normal blood picture can be determined, from which, for instance, a pathological defect or a risk factor can be determined, at least it can be indicated that further examination thereof is advisable or necessary. Of course, a healthy blood picture may also be determined.
- In U.S. 2003/0175167 A1, an apparatus is described with which an amount of blood can be received in a chamber, the blood being diluted and then at least partly being pressed through a filter. The filter is chosen such that at least the blood plasma from the blood can pass this filter and is collected in a collecting space, while at least the red blood cells from the blood cannot pass the filter and remain behind the chamber. Then a seal is provided in the passage between this chamber and the collecting space, so that the plasma cannot flow back. The apparatus is subsequently sent to a laboratory in order to carry out an analysis of the plasma. Here, it is particularly important that the separation between the plasma and the red blood cells is maintained, because otherwise, for instance, coagulation could occur, which makes the blood unusable for various tests afterwards. The analysis of the blood plasma is done by, for instance, spectral analysis.
- U.S. 2004/0133146 A1 describes an apparatus, where blood is sucked up with the aid of a thin tube, which blood is then supplied into a chamber, after which it is pressed against a filter with the aid of a piston, such that at least the blood plasma is forced through the filter and at least the red blood cells remain behind in the chamber. The separated blood plasma can then be examined, for instance with spectral analysis.
- Compared to whole blood analysis, these apparatuses have the advantage that the blood does not need to be centrifuged. Thus, much less blood needs to be tapped and tests can be carried out more quickly.
- These known apparatuses and the methods to be carried out therewith have the drawback that they still take up relatively much time before a test result is known to the patient whose blood has been tapped. This is because, although only little blood needs to be tapped and it does not need to be centrifuged anymore, the analysis needs to be carried out in a laboratory, so that, for sending and processing, relatively much time is needed. In addition, it can be experienced as a drawback by the patient that others get to know the results, even before the patient himself or herself.
-
GB 2 392 854 describes a filtration apparatus provided with a first chamber and a second chamber, mutually separated by a filter membrane. In one embodiment, this apparatus is described for the separation of blood into plasma and other blood components. In this embodiment, the second chamber is provided with a hollow plunger with the filter element at the leading end. Prior to use, in the second chamber, there are beads comprising reagent for a substance in the blood plasma. During use, the plunger is pressed into whole blood in the first chamber, so that blood plasma is forced through the filter into the second chamber. The beads dissolve in the blood plasma and react with the substance to be detected, so that a color change occurs as an indication of the presence of that substance. This test takes at least ten minutes. -
EP 1 221 340 describes a universal testing apparatus in which different reagents can be provided, between or on filters. All kinds of liquids to be analyzed, such as whole blood, serum, foodstuffs and the like can be led along them for obtaining reactions. For use of serum, it is described that a gel with reagent can be provided between the filters. The filters then serve to clean the serum. Serum is separated from whole blood outside the apparatus and is introduced into the apparatus as such. - EP 1152 241 describes an apparatus, in a series of embodiments, where at least three chambers are used for sequentially separating parts of whole blood, in order to collect blood plasma in a last chamber. Separation of different fractions of the blood is at least partly brought about by centrifugation.
- U.S. Pat. No. 3,481,477 describes an apparatus for separating whole blood into serum and solid parts. To this end, a piston is provided in a tube, with the end of the piston being provided with a filter. Filter tablets can be provided for forming the filter. To the filter, a thin capillary tube is connected. During use, blood is introduced into the tube, after which the piston with the filter is pressed against the blood. Serum is forced by the filter tablets and is discharged via the capillary tube to a test tube or a reservoir formed in the inside of the piston. The filter tablets can contain a reagent for filtering components from the serum.
- These known apparatuses have a complex structure and are complex to use and do not produce a desired quick, reliable result directly readable for a user.
- Further, from for instance U.S. Pat. No. 4,477,575, an apparatus is known where use is made of reagents, where, on a test apparatus, a drop of blood is deposited, on top of a filter. Under the influence of capillary action and/or gravity, blood plasma is led through a filter layer while the red blood cells remain behind on the filter. In or near the filtering layer, a reagent is provided which can react with a component in the blood plasma. After that, a visual inspection of the reagent, at least the apparatus, can give a decisive answer about the presence or absence of this component in the blood. DE 29 22 958 furthermore describes multilayer filters with different reagents for different pathological or otherwise indicative factors in blood.
- Such an apparatus offers the advantage that it can be carried out by a patient himself or herself or in his or her presence, so that the time for obtaining the test results can be reduced considerably. However, such tests also still require a few minutes or more, which is in many cases undesired. In addition, these tests have the drawback that they are very sensitive to, for instance, pollution from outside, since the apparatus is open, while, in addition, the degree of separation and consequently the amount of blood plasma obtained cannot he determined sufficiently accurately. Particularly when multilayer filters are used with different reagents, this drawback is increased further because it is unclear bow much blood plasma ends up on which layer of the filter.
- The invention contemplates providing an apparatus and/or method for analyzing blood.
- The invention particularly contemplates providing a method and/or apparatus for relatively quickly separating at least blood plasma and red blood cells from whole blood and then analyzing at least the blood plasma.
- A further object of the invention is providing a method and/or apparatus with which a user can carry out blood tests independently and relatively quickly.
- The invention further contemplates providing an apparatus and/or method which enables separation and analysis of blood, where indications can be given of threshold values of one or more blood-related factors.
- In a first embodiment, an apparatus according to the invention is characterized in that at least separating means for separating blood plasma and red blood cells are included, which separating means comprise pressure means for pressing at least a part of the blood through a filter, while at least first collecting means are provided for collecting separated blood plasma and at least one reagent which is provided in these first collection means or can be introduced therein for reaction with substances or organisms present in this blood plasma.
- With such an apparatus, the advantage is achieved that at least blood plasma is separated under pressure from at least red blood cells, so that virtually instantaneously, the desired separation of blood plasma and red blood cells is obtained. In addition, at least the blood plasma is collected in collecting means in which the blood plasma directly comes or can be brought into contact with at least one reagent, so that, within a particularly short time, it can be determined whether a particular component in the blood of the respective is present, at least exceeds a particular value or limit. Preferably, use is made of reagents which allow visually determination of whether or not a respective reaction occurs, for instance by color change, structural change such as coagulation, dissolving, or the like.
- The blood plasma is preferably collected in the first collecting means, designed as a space, separated from the environment, so that no pollution or leaking out of blood plasma can occur. Preferably, prior to use, in the apparatus, a known amount of diluent liquid is provided, in particular in above-mentioned chamber, while, in addition, a known amount of blood is introduced, so that the degree of dilution of the blood is always accurately known. Thus, accurate test results can be achieved quickly and simply.
- In a first particularly advantageous embodiment, the at least one reagent is provided in the first collecting means, in particular on a wall part thereof. Preferably, this wall part is at least partly transparent so that change of, for instance, color or structure of the reagent is clearly visible from the outside of the apparatus, at least of the first collecting means, without these needing to be opened.
- In an alternative embodiment, the at least one reagent is provided on an element or in an element which is or can be inserted into the first collecting means. This offers at least the advantage that the apparatus can have a substantially universal design, while, each time, a suitable reagent can be chosen, depending on the test to be carried out.
- With an apparatus and method according to the invention, preferably, the reagent is chosen and/or dosed such that end point values can be determined, so that it can at least be seen whether a particular factor in the blood is above or below a preselected value.
- In a particular embodiment, the apparatus is provided with a piston with which the blood, at least the blood plasma, can be pressed through a filter, while the first collecting means are preferably provided in the piston. The at least one reagent may then be provided on or in the piston.
- In an apparatus and method according to the invention, each time, one reagent can be used, but combinations of reagents may also be provided, for simultaneously carrying out a series of tests. Thus, for instance, on a wall of the first collecting means, rings, surfaces or the like of different reagents may be provided. Optionally, of course, a reagent may also be provided in a different aggregation condition, for instance liquid or in the form of a solid.
- In an alternative embodiment, the at least one reagent is provided in or on a separate holder, while the apparatus for separating the blood is provided with a pouring opening, particularly near the first collecting means, so that, after the blood plasma has been separated from the red blood cells, it can be poured into or on this holder, at least this at least one reagent.
- The at least one reagent is preferably chosen from the group of reagents which only indicate presence of a substance or organism in the blood plasma and not a value for the concentration or the like. Preferably, the at least one reagent is therefore essentially binary: reaction of the reagent indicates, for instance by color change, coagulation or other transformation of the reagent, the blood plasma or a reaction between them, whether a particular threshold value is exceeded or not. For instance, a reagent which can indicate the presence of Helicobacter Pylori or a reagent which indicates an excess or limiting amount of coagulation factors. Also, reagents can be used which can indicate the presence of antigens, for instance a degree in which they are to be present or that a limit value is exceeded, for instance antigens with which the presence of tumors can be demonstrated or at least can be shown to be plausible. Also, reagents can be used with which the presence of, for instance, vitamins can he determined. Reagents can further be used with which, in case of exceeding or, conversely, falling short of a limit value, it can be indicated whether the exceeding is harmful to a patient. Such a reagent can advantageously be combined with a reagent which indicates exceeding or falling short of this limit value. Further, reagents can be used with which a therapeutic or non-therapeutic blood level can be determined, for instance of a medicine or toxic, for instance a medicine depending, for an optimal effect, on an optimal blood level or on a blood level which is not to be exceeded due to, for instance, undesired side effects. Combinations of reagents as mentioned may also be used. These reagents and uses are of course only mentioned by way of illustration and should not be taken as being limitative in any way.
- By way of illustration of the invention, embodiments of an apparatus and method according to the invention will be explained in more detail with reference to the drawing, in which:
-
FIG. 1 shows, in cross-sectional view, prior to use. an apparatus according to the invention, in a first embodiment; -
FIG. 2 shows, in partly retracted condition, an apparatus according toFIG. 1 ; -
FIG. 3 shows, in wholly retracted condition, an apparatus according toFIGS. 1 and 2 ; -
FIGS. 4A and B show, in partly cross-sectional side elevational view, an alternative embodiment of an apparatus according to the invention, in a starting position and an end position, respectively; -
FIG. 4C schematically shows, in cross-sectional side elevational view, a filter for an apparatus according toFIG. 4 ; -
FIG. 5 schematically shows an insertion element for use with an apparatus according to the invention; and -
FIG. 6 shows, in side elevational view, a trunk of an apparatus according toFIG. 1 , in an alternative embodiment. - In this description, same or corresponding parts are designated by same or corresponding reference numerals. Here, not all reference numerals are given in each of the drawings. The embodiments shown and discussed all involve separation and analysis of blood. However, other biological samples may be tested with a same or similar apparatus. The embodiments of apparatuses and reagents given in the examples are only shown by way of illustration and should not be taken as being limitative in any way.
-
FIG. 1 shows, in partly cross-sectional side elevational view, anapparatus 1 according to the invention, in a first embodiment, in two parts. InFIG. 1 , on the left side, afirst part 2 is shown, formed by a transparentplastic casing 3, closed on a bottom side by a sharply taperingbottom 4 and open on theopposite side 5. Theopen side 5 is provided with aneck 6 withexternal screw thread 7 on which acap 8 is screwed. Thecap 8 clamps agasket 9 on theneck 6, so that the inner space orchamber 10 within thecasing 3 is closed off. In thechamber 10, adiluent liquid 11 is received, in a predetermined amount. -
FIG. 1 shows, on the right side,second part 20 in the form of apiston part 12, comprising an at least partly transparenttubular part 13 with an openbottom end 14 and an opposite opentop end 15, surrounded by acollar 16. Around the outside of thebottom end 14, aflexible ring 17 is provided with an outer diameter Db which matches the inner diameter Di of thecasing 3 of thefirst part 2 in a manner to be described in more detail. In thetubular part 13, atrunk 18 is inserted, which has an outer diameter D1 which is smaller than the inner diameter D2 of thetubular part 13. On the top side of thetrunk 18, acollar part 19 is provided which, on the top side, connects to anapron 21 extending outwards and is provided with aninternal screw thread 22 which fits on theexternal screw thread 7 of thefirst part 2. The collar part sealingly fits into thetop end 15, while the apron can abut the outside of thecollar 16. Thetrunk 18 and thecollar part 19 have such a length that, in the position shown inFIG. 1 , thebottom end 24 of thetrunk 18 is at some distance from thebottom end 14 within thetubular part 13. On thebottom end 24 of thetrunk 18, astop 25 is placed, which will further be explained. - In the
bottom end 14 of thetubular part 13, afilter 26 is provided through which at least blood plasma can pass, but through which red blood cells cannot pass, at least with some dilution of the blood. Examples of filters and dilutions to be used are given in U.S. 2003/1075167 A1, which are not to be taken as being limitative in any way. -
FIG. 2 shows thesecond part 20 in a condition where it is partly retracted into thefirst part 2, where a drop of blood with known volume is 15 mixed into the diluent liquid. In this condition, thefilter 26 lies on the diluted blood and thering 17 seals against the inside of thecasing 3. Thus, thechamber 10 is closed. From this position, thesecond part 20 can be pressed downwards further, in the direction of thebottom 4. Here, thefilter 26 is forcefully pressed against the diluted blood, so that blood plasma is pressed upwards through thefilter 26 while the red blood cells are stopped and remain behind in thechamber 10. Between thetrunk 18, thetubular part 13, thefilter 26 and thecollar part 19, first collecting means 27 are formed, in the form of a ring chamber, in which the blood plasma is collected. -
FIG. 3 shows, in cross-sectional side elevational view, anapparatus 1 according to the invention, where thesecond part 10 is completely pressed into thefirst part 2, so far that theinternal screw thread 22 is screwed on theexternal screw thread 7 and thestop 25 closes off the open end of thetubular part 13 above thefilter 26, so that theblood plasma 28 is prevented from flowing back from the first collecting means 27. - In the embodiment shown in
FIGS. 1-3 , on the inside of thetubular part 13, at least onesurface 29 is provided which contains areagent 30 for at least one element which is present, at least can be present, in theblood plasma 28. Preferably, thereagent 30 is provided as a ring-shaped surface, so that it is visible from the outside from all sides of the assembledapparatus 1. This allows reaction of thereagent 30 with above-mentioned element to be observed clearly, for instance due to color change, structural change, clotting, dissolving, or the like, if this element is present to a particular degree in the blood plasma. It will be clear that thereagent 30 or reagents can be chosen on the basis of the elements whose presence, concentration, level or the like needs to be determined. If desired, two ormore surfaces different reagents - In an alternative embodiment shown in
FIG. 6 , the reagent is provided on thetrunk 18 in the form of a ring-shapedsurface 29. Thus, the advantage is achieved that thetrunk 18 can be chosen, for instance from a set oftrunks 18 with different reagents, depending on the desired elements to be determined. Incidentally, this may of course also be achieved with differenttubular elements 13 with different reagents. In an alternative embodiment, an apparatus according to the invention may be supplied with a series of insertion elements such as (hollows)rods 31, rings 32 or the like as schematically shown inFIG. 6 , where the different insertion elements carrydifferent reagents tubular element 13. Ring-shaped elements can then, for instance, be slid around thetrunk 18 for forming atrunk 18 as shown inFIG. 6 . Rods or the like may, for instance be placed in openings or slots in thetrunk 18 or in a jacket or chamber enclosing the or each trunk, such as aspace 27 or atube 13, for instance loosely inserted. -
FIG. 5 schematically shows. in perspective view, an alternative embodiment of aninsertion element 32 for use in an apparatus according toFIGS. 1-3 . Thisinsertion element 32 is substantially formed by a hollowcylindrical body 50, which comprises a ring-shapedportion 52 at afirst end 51, from which a number offingers 53 extend, in the direction of an oppositesecond end 54. Near thissecond end 54, thefingers 53 have areduction 55 in that aportion 56 of each finger is offset inwards with respect to anouter surface 57 of above-mentionedbody 50. On the outwardly facingsurface 29 of thereduction 55, on eachfinger 53, areagent 30 is provided. This may be the same reagent on each finger, but also, ondifferent fingers 53,different reagents cylindrical body 50 has an outer diameter D3 which is approximately equal to the inner diameter D2 of thebody 13, so that it can be retracted into thebody 13 from thetop end 15, preferably with thefingers 53 in the direction of theend 14. Theouter surface 57 can then abut the inside of thebody 13, while thesurface 29 is kept at a distance therefrom. This allows thereagent space 27. Of course, the reagent may also be provided in a different manner, for instance directly on thesurface 57, if it is kept at a distance from the wall of thebody 13, or on an inwardly facing surface of theinsertion part 32, in which case it is advantageous when at least thefingers 53 are at least partly transparent at the height of thereagent 30. - In this description, reagent or reagents or similar terms are also at least understood to mean antibodies or enzymes, which means that tests can he applied which are based on antibodies or enzymes.
- Different reagents and other markers may be used, such as for instance antigens, chemical reagents, enzymes, chemical markers and the like. Reagents and markers may, for instance, he used for indicating problems with a heart, liver, kidney or other organs, glucose abnormalities such as diabetes, cholesterol abnormalities, abnormalities in one or more hormones, blood values in general and the like, viral or bacterial abnormalities such as influenza, malaria, hepatitis, HIV, inflammations, MS, ME and other indicators, in particular for existing health problems and/or health problems possibly to he expected. Herein, abnormalities are understood to mean such deviations from values normally expected for a respective person that, for a doctor, these would be or should be a reason to carry out further examinations or to intervene by, for instance, administering medicines, liquids, nutrients or to intervene surgically.
- Examples of
reagents 30, to which the invention is by no means limited, are for instance antibodies for HTLV I and/or II, cystatin C or similar markers for kidney functions or heart functions such as cardiovascular problems, heart infarcts ((myocardial) infarct) and/or heart attack (stroke), monoclonal antibodies, coagulation reagents such as lupus anticoagulant-sensitive or insensitive reagents, PSA antigen, HBS-1, HLA antibodies, HbA(1c) or GlyHb in hemoglobin measurement. - In a first example of an embodiment, on the inside of the
tubular part 13, asurface 29 of cholesterol reagent, CHOD-Pap, BoehringerMannheim GmbH is provided as areagent 30, which reagent 30 is suitable for demonstrating cholesterol (total cholesterol, HDL or LDL). In thechamber 10, 220 microliters of diluent liquid (buffer) were provided, after which 60 microliters of blood were diluted therein. By pressing down the second part into the first part, as described, in thefirst space 27, 220 microliters of blood plasma were collected. This blood plasma was brought into contact with the reagent by agitation (horizontal rocking), so that the reagent changed color from a neutral color to a characteristic color, in this case red, clearly visible from the outside. It was thus found that the cholesterol level in the blood was higher than a threshold value of 6.5 mmol/l. Control measurements of the whole blood taken via a venous blood sample and tested in laboratory demonstrated that the blood indeed had a value above that threshold value. -
FIGS. 4A and B schematically show anapparatus 1 according to the invention, in an alternative embodiment, the basis of which is described in NL 1016646, which publication is understood to be incorporated herein by reference, at least with regard to the operation for separating plasma from blood. - This
apparatus 1 comprises a hollowcylindrical body 33 in which afirst piston 34 is sealingly movable with the aid of apressure body 35 which, in a first position, rests against an end of thetrunk 36 connected with the first piston and, in a second position, for instance rotated with respect to the first position through an angle of about 90 degrees about a longitudinal axis of thebody 33, over thetrunk 36. So, in the first position, thefirst piston 34 can be pressed in the direction of abottom end 37 of thebody 33 with the aid of thepressure body 35, up to against astop 38. Asecond piston 39 withtrunk 46 is provided around thetrunk 36 and seals against both the trunk and the inside of thebody 33. Thesecond piston 39 is, for instance, a rubber ring. Between the first and thesecond piston treatment space 40 is enclosed, the volume of which is variable. Therein, a treatment fluid or other material can be included, such as abuffer 11, for instance a phosphate buffer, similar toFIGS. 1-3 . - In a
wall 44 of thebody 33, aninlet opening 42 and an outlet opening 43 are provided. A capillary 44 can be inserted into the inlet opening, so that the contents of the capillary 44 can be sucked into the body, between the twopistons treatment space 40, as will be discussed hereinbelow. To the outlet opening 43, afilter 26 connects, into which and/or through which at least the contents of thetreatment space 40 can be forced. - In a starting position, shown in
FIG. 4A , thepistons body 33 and relatively close to each other. The inlet opening preferably opens just into the treatment space, whichtreatment space 40 has a relatively small volume. A capillary 44 filled withwhole blood 45 as a sample is inserted into theinlet opening 42. By now pressing thefirst piston 34 in the direction of thebottom end 37 of the body, it passes the outlet opening 43 while, in addition, the volume of thetreatment space 40 is increased, in that thesecond piston 39 will not or at least not completely follow the movement of thefirst piston 34 in a first part of the maximum stroke, i.e. the maximum distance over which thepressure body 35 can move from the starting position in the direction of thebottom end 37, before it is brought into the second position. Because the volume of thetreatment space 40 increases, the contents of the capillary will be sucked into the treatment space and mix therein with thetreatment fluid 11. - Then the pressure body is brought into the second position with respect to the
trunk 36, so that it can be pressed further in the direction of thebottom end 37, over thetrunk 36, thus pressing thesecond piston 39 is the direction of thefirst piston 34. The volume of the treatment chamber is thereby reduced back, in particular minimized, and the mixture of the treatment fluid and the sample is pressed through the outlet opening 43, into and/or through thefilter 26. The filter may be any suitable filter, for instance a glass fiber filter. Here, plasma is separated from the blood, in that the plasma is pressed through the filter, with blood particles such as erythrocytes and leukocytes removed. - According to the invention, in and/or to the
filter 26, at least onetest surface 29 is provided as shown inFIG. 4C , formed by or comprising areagent 30, such as for instance mentioned hereinabove. Because the plasma is forced through the filter, it directly and intensively comes into contact with the or eachtest surface 29 and consequently with the or eachreagent 30, so that the test result can be read out virtually instantaneously. An advantage is that it does not need to be provided on an external reagent surface, so that pollution of the plasma and/or the reagent can be prevented. In addition, the plasma can be collected in thefilter 26, at least thehousing 47 thereof, so that pollution and in particular contamination of the environment can be prevented. This is particularly important in use of biological samples such as blood in which pathogenic elements may be present. -
FIG. 4C schematically shows afilter 26 for anapparatus 1 according toFIGS. 4A and B, which filter 26 comprises ahousing 47. Thehousing 47 is at least partly and preferably wholly transparent, such that thefilter surface 48 or at least a part thereof on whichreagent 30 is provided can be seen without thehousing 47 needing to be opened. This prevents pollution of plasma, reagent and/or the environment. Thehousing 47 may, for instance, comprise twohousing parts filter element 57 as described earlier, for separation of blood plasma and blood corpuscles. On a side operatively facing the outlet opening 43, in thefirst housing part 48, achamber 58 is provided in which blood corpuscles remain behind, above thefilter element 57. In thesecond housing part 49, a collectingspace 27 is provided in which the separatedplasma 28 is collected. In this space, at least onesurface 29 is provided on which or in which a reagent can be included for reaction with the blood plasma. Thissurface 29 may, for instance, be provided on thefilter element 57, on the side thereof facing the collectingspace 27, while it may, for instance, have a porous design, so that intensive contact is obtained between plasma and reagent. Thesurface 29 may also, as shown inFIG. 4C , be provided on the inside of thehousing 47, in the collectingspace 27, or both. In this embodiment, thesecond housing part 49 has a transparent design, at least at the height of thesurface 29, here provided on a block 59, so that, for instance, discoloration of the block as a result of the reaction between elements of or in the plasma and the or areagent 30 is visible from outside thehousing 47. - The invention is by no means limited to the embodiments given in the drawing and description. Many variations thereof are possible within the framework of the invention described by the claims.
- Thus, with use of a filter. a housing can be used in which the plasma is at least partly collected, while the housing is at least partly transparent and the or each reagent is provided therein. This offers the advantage of good protection against pollution and/or contamination. In addition, the apparatus or at least the plasma collected therein can then be used for further tests. Thus, the apparatus as a whole or the filter and/or the housing may, for instance, be sent to a laboratory, where further tests can be carried out to, for instance, verify a first indication obtained with the or a reagent or to examine it further.
Claims (20)
1. A method for analyzing blood, comprising:
separating an amount of blood into at least blood plasma and red blood cells by pressing the amount of blood through a filter to provide separated blood plasma and red blood cells, wherein blood plasma passes the filter but red blood cells do not; and
collecting the separated blood plasma in a first collecting chamber, wherein the first collecting chamber comprises at least one reagent capable of reacting with a substance or an organism in the separated blood plasma.
2. The method of claim 1 , wherein the separated blood plasma in the first collecting chamber is brought into contact with the at least one reagent under conditions wherein a reaction occurs between the at least one reagent and the substance or organism in the separated blood plasma.
3. The method of claim 2 , wherein the reaction produces a detectable indicator.
4. The method of claim 3 , wherein the detectable indicator comprises a color change, structural change, or other transformation of the reagent.
5. The method of claim 3 , wherein the detectable indicator can be observed from the outside of the first collecting chamber.
6. The method of claim 5 , wherein the detectable indicator allows visual determination of whether or not the reaction occurs.
7. The method of claim 6 , wherein the detectable indicator can be observed virtually instantaneously.
8. A method for analyzing blood, comprising:
mixing a preselected amount of blood with a preselected amount of a diluent to obtain a desired dilution;
separating the diluted blood into at least blood plasma and red blood cells by pressing the diluted blood through a filter to provide separated blood plasma and red blood cells, wherein blood plasma passes the filter but red blood cells do not;
collecting the separated blood plasma in a first collecting chamber, wherein the first collecting chamber comprises at least one reagent capable of reacting with a substance or an organism in the separated blood plasma; and
contacting the at least one reagent in the first collecting chamber with the separated blood plasma under conditions wherein a reaction occurs between the at least one reagent and the substance or organism in the separated blood plasma, and wherein the reaction produces a detectable indicator.
9. The method of claim 8 , wherein the detectable indicator can be observed from the outside of the first collecting chamber.
10. The method of claim 9 , wherein the detectable indicator allows visual determination of whether or not the reaction occurs.
11. The method of claim 10 , wherein the detectable indicator can be observed virtually instantaneously.
12. The method of claim 8 , wherein the at least one reagent is a reagent or marker for indicating a heart disease or condition, a liver disease or condition, a kidney disease or condition, a glucose abnormality, diabetes, a cholesterol abnormality, a hormone abnormality, a blood value, a viral infection, a bacterial infection, influenza, malaria, hepatitis, HIV, inflammation, multiple sclerosis, or myalgic encephalopathy, or is selected from the group consisting of an antibody for HTLV I, an antibody for HTLV II, cystatin C, a marker for kidney function, a marker for heart function, a marker for a cardiovascular disease or condition, a marker for heart infarction, a marker for myocardial infarction, a marker for heart attack, a marker for stroke, a monoclonal antibody, a coagulation reagent, a lupus anticoagulant-sensitive reagent, a lupus anticoagulant-insensitive reagent, PSA antigen, HBS-1, a HLA antibody, HbA(1c), GlyHb, and a marker for hemoglobin level.
13. A method for analyzing blood, comprising:
separating an amount of blood into at least blood plasma and red blood cells by pressing the amount of blood through a filter to provide separated blood plasma and red blood cells, wherein blood plasma passes the filter but red blood cells do not;
collecting the separated blood plasma in a first collecting chamber, wherein the first collecting chamber comprises at least one reagent capable of reacting with a substance or an organism in the separated blood plasma, and wherein the first collecting chamber is at least partly transparent, such that the at least one reagent is at least partly visible from the outside of the first collecting chamber; and
contacting the at least one reagent in the first collecting chamber with the separated blood plasma under conditions wherein a reaction occurs between the at least one reagent and the substance or organism in the separated blood plasma, and wherein the reaction produces a detectable indicator.
14. The method of claim 13 , wherein the detectable indicator can be observed from the outside of the first collecting chamber.
15. The method of claim 13 , wherein the at least one reagent is provided on a wall part of the first collecting chamber.
16. The method of claim 13 , wherein the at least one reagent is provided on an element or in an element which is inserted into the first collecting chamber.
17. The method of claim 13 , wherein the at least one reagent is provided in liquid form.
18. The method of claim 13 , wherein the at least one reagent is provided in solid form.
19. The method of claim 13 , wherein at least two reagents are provided in the first collecting chamber.
20. The method of claim 13 , wherein the at least one reagent is a reagent or marker for indicating a heart disease or condition, a liver disease or condition, a kidney disease or condition, a glucose abnormality, diabetes, a cholesterol abnormality, a hormone abnormality, a blood value, a viral infection, a bacterial infection, influenza, malaria, hepatitis, HIV, inflammation, multiple sclerosis, or myalgic encephalopathy, or is selected from the group consisting of an antibody for HTLV I, an antibody for HTLV II, cystatin C, a marker for kidney function, a marker for heart function, a marker for a cardiovascular disease or condition, a marker for heart infarction, a marker for myocardial infarction, a marker for heart attack, a marker for stroke, a monoclonal antibody, a coagulation reagent, a lupus anticoagulant-sensitive reagent, a lupus anticoagulant-insensitive reagent, PSA antigen, HBS-1, a HLA antibody, HbA(1c), GlyHb, and a marker for hemoglobin level.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/989,068 US20180264463A1 (en) | 2007-02-09 | 2018-05-24 | Apparatus and method for separating and analyzing blood |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL1033365A NL1033365C2 (en) | 2007-02-09 | 2007-02-09 | Device and method for separating and analyzing blood. |
NL1033365 | 2007-02-09 | ||
PCT/NL2008/050072 WO2008097091A1 (en) | 2007-02-09 | 2008-02-08 | Apparatus and method for separating and analyzing blood |
US52639410A | 2010-09-24 | 2010-09-24 | |
US15/989,068 US20180264463A1 (en) | 2007-02-09 | 2018-05-24 | Apparatus and method for separating and analyzing blood |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/526,394 Division US9993816B2 (en) | 2007-02-09 | 2008-02-08 | Apparatus and method for separating and analyzing blood |
PCT/NL2008/050072 Division WO2008097091A1 (en) | 2007-02-09 | 2008-02-08 | Apparatus and method for separating and analyzing blood |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180264463A1 true US20180264463A1 (en) | 2018-09-20 |
Family
ID=38476101
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/526,394 Expired - Fee Related US9993816B2 (en) | 2007-02-09 | 2008-02-08 | Apparatus and method for separating and analyzing blood |
US15/989,068 Abandoned US20180264463A1 (en) | 2007-02-09 | 2018-05-24 | Apparatus and method for separating and analyzing blood |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/526,394 Expired - Fee Related US9993816B2 (en) | 2007-02-09 | 2008-02-08 | Apparatus and method for separating and analyzing blood |
Country Status (7)
Country | Link |
---|---|
US (2) | US9993816B2 (en) |
EP (1) | EP2122349A1 (en) |
JP (1) | JP2010518393A (en) |
CN (1) | CN101663580B (en) |
NL (1) | NL1033365C2 (en) |
RU (1) | RU2462717C2 (en) |
WO (1) | WO2008097091A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL1033365C2 (en) * | 2007-02-09 | 2008-08-12 | Medavinci Dev B V | Device and method for separating and analyzing blood. |
CN102149472B (en) | 2008-07-21 | 2014-08-13 | 贝克顿·迪金森公司 | Density phase separation device |
AU2009274096B2 (en) | 2008-07-21 | 2012-08-02 | Becton, Dickinson And Company | Density phase separation device |
MX366109B (en) | 2008-07-21 | 2019-06-26 | Becton Dickinson Co | Density phase separation device. |
NZ596537A (en) | 2009-05-15 | 2014-11-28 | Becton Dickinson Co | Density phase separation device |
US9919248B2 (en) * | 2010-12-21 | 2018-03-20 | Ge Healthcare Uk Limited | Filtration device and method |
JP5730695B2 (en) * | 2011-02-15 | 2015-06-10 | 株式会社雅精工 | Blood separation cylinder |
KR101092128B1 (en) | 2011-06-14 | 2011-12-12 | 주식회사 나노엔텍 | Sampler |
WO2013023089A1 (en) | 2011-08-09 | 2013-02-14 | Eccentric | Devices and methods for overlaying blood or cellular suspensions |
US10220384B2 (en) | 2011-08-09 | 2019-03-05 | Jae Go Kwon | Devices and methods for overlaying blood or cellular suspensions |
PL3617697T3 (en) * | 2012-02-16 | 2022-08-16 | Smiths Detection-Watford Limited | Synchronised ion modification |
US9213043B2 (en) | 2012-05-15 | 2015-12-15 | Wellstat Diagnostics, Llc | Clinical diagnostic system including instrument and cartridge |
US9625465B2 (en) | 2012-05-15 | 2017-04-18 | Defined Diagnostics, Llc | Clinical diagnostic systems |
US9075042B2 (en) | 2012-05-15 | 2015-07-07 | Wellstat Diagnostics, Llc | Diagnostic systems and cartridges |
JP6286674B2 (en) * | 2012-10-22 | 2018-03-07 | パナソニックIpマネジメント株式会社 | Filter device |
US20150048085A1 (en) | 2013-08-16 | 2015-02-19 | Corning Incorporated | Vessels and methods for cryopreservation |
US20150076069A1 (en) * | 2013-09-13 | 2015-03-19 | Scientific Plastic Products, Inc. | Filter vial with limited piston stroke |
WO2015098967A1 (en) * | 2013-12-24 | 2015-07-02 | 東亜ディーケーケー株式会社 | Reagent container, reagent-filled reagent container, reaction unit, and analysis system |
US9694359B2 (en) | 2014-11-13 | 2017-07-04 | Becton, Dickinson And Company | Mechanical separator for a biological fluid |
CN108347917B (en) * | 2015-11-16 | 2021-08-24 | 康宁股份有限公司 | Low-temperature storage device |
JP6905522B2 (en) | 2015-11-16 | 2021-07-21 | コーニング インコーポレイテッド | Cryogenic vial assembly |
US10638748B2 (en) | 2015-12-22 | 2020-05-05 | Corning Incorporated | Break away/tear away cryopreservation vial and methods for manufacturing and using same |
CN105974141A (en) * | 2016-05-09 | 2016-09-28 | 温冬梅 | Novel multi-mode automatic analysis system of glycated hemoglobin HbA1c |
US11185863B2 (en) * | 2016-09-30 | 2021-11-30 | Koninklijke Philips N.V. | System for applying a reagent to a sample |
CN110461473B (en) * | 2016-11-16 | 2021-11-05 | 奎多公司 | Whole blood separation device |
US20200299677A1 (en) | 2017-10-27 | 2020-09-24 | Juno Diagnostics, Inc. | Devices, systems and methods for ultra-low volume liquid biopsy |
JP7382071B2 (en) * | 2018-09-28 | 2023-11-16 | 積水メディカル株式会社 | How to measure glycated hemoglobin (%) |
CN109332007B (en) * | 2018-10-16 | 2020-12-29 | 江苏省肿瘤医院 | Plasma separation device and plasma separation method |
JP7228676B2 (en) * | 2019-03-25 | 2023-02-24 | 富士フイルム株式会社 | Biological sample separation device |
CN110903952B (en) * | 2019-11-06 | 2023-05-26 | 天晴干细胞股份有限公司 | Method for separating and purifying placenta blood and resuscitating by using protective liquid and placenta extruder |
CN111821718B (en) * | 2020-04-29 | 2021-10-29 | 漳州职业技术学院 | Magnolia liliiflora polysaccharide strontium antiallergic agent production line and preparation method thereof |
CN111870258B (en) * | 2020-07-31 | 2023-07-21 | 武汉轻工大学 | Animal blood serum high-efficiency separating needle |
CN111870259B (en) * | 2020-07-31 | 2023-09-29 | 武汉轻工大学 | Blood collection serum separation needle for animals |
JP7418823B2 (en) | 2020-09-24 | 2024-01-22 | 大扇産業株式会社 | Specimen collection container |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458020A (en) * | 1982-11-15 | 1984-07-03 | Quidel | Integrated single tube plunger immunoassay system having plural reagent chambers |
US5776563A (en) * | 1991-08-19 | 1998-07-07 | Abaxis, Inc. | Dried chemical compositions |
US5830352A (en) * | 1994-12-02 | 1998-11-03 | Bristol-Myers Squibb Company | Centrifuge reagent delivery system |
US20030108447A1 (en) * | 1997-09-16 | 2003-06-12 | Masayuki Yokoi | Blood test container and blood test method |
US6632681B1 (en) * | 2000-07-24 | 2003-10-14 | Ey Laboratories | Reagent delivery device and method of use |
US20040203083A1 (en) * | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
US20060063180A1 (en) * | 2004-09-17 | 2006-03-23 | Yoshihiro Yamashita | Method of nucleic acid isolation |
US9182417B2 (en) * | 2008-05-14 | 2015-11-10 | Fabpulous B.V. | Device and method for separating and analyzing blood |
US9327284B2 (en) * | 2004-01-21 | 2016-05-03 | Orion Diagnostica Oy | Sampling and assay device |
US9993816B2 (en) * | 2007-02-09 | 2018-06-12 | Fabpulous B.V. | Apparatus and method for separating and analyzing blood |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3481477A (en) * | 1965-03-02 | 1969-12-02 | Andrew F Farr | Apparatus for filtering out clear liquid from suspended solids |
US3931018A (en) * | 1974-08-09 | 1976-01-06 | Becton, Dickinson And Company | Assembly for collection, separation and filtration of blood |
JPS587332Y2 (en) | 1978-06-06 | 1983-02-08 | 富士写真フイルム株式会社 | Multilayer blood chemistry analysis material |
DE3029579C2 (en) * | 1980-08-05 | 1985-12-12 | Boehringer Mannheim Gmbh, 6800 Mannheim | Method and means for separating plasma or serum from whole blood |
EP0188599A1 (en) * | 1984-07-17 | 1986-07-30 | International Health Services, Inc. | Method and apparatus for filtering particulate matter from fluids of biomedical interest and examining same |
US4918025A (en) | 1987-03-03 | 1990-04-17 | Pb Diagnostic Systems, Inc. | Self contained immunoassay element |
EP0508010A1 (en) | 1991-04-10 | 1992-10-14 | La Mina Ltd. | Biological fluids testing membrane module and method of conducting same |
JPH05188053A (en) | 1992-01-10 | 1993-07-27 | Sanwa Kagaku Kenkyusho Co Ltd | Instrument for separating serum or plasma component from blood |
ZA948564B (en) * | 1993-11-19 | 1995-07-26 | Bristol Myers Squibb Co | Liquid separation apparatus and method |
US6171870B1 (en) * | 1998-08-06 | 2001-01-09 | Spectral Diagnostics, Inc. | Analytical test device and method for use in medical diagnoses |
US6280400B1 (en) | 1998-12-05 | 2001-08-28 | Becton Dickinson And Company | Device and method for separating component of a liquid sample |
US6375817B1 (en) * | 1999-04-16 | 2002-04-23 | Perseptive Biosystems, Inc. | Apparatus and methods for sample analysis |
DE19950001A1 (en) * | 1999-10-15 | 2001-04-19 | Deutsche Telekom Mobil | Method for selection, transmission and playback of pieces of music by participants in a digital mobile communication system |
US6379708B1 (en) | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
US6969367B2 (en) | 2000-02-02 | 2005-11-29 | Xepmed, Inc. | Extracorporeal pathogen reduction system |
US7470245B2 (en) | 2000-02-02 | 2008-12-30 | Xepmed, Inc. | Extracorporeal pathogen reduction system |
CA2402314C (en) * | 2000-03-10 | 2009-12-08 | Universite De Geneve | Diagnostic assay for transmissible spongiform encephalopathies |
NL1016646C2 (en) * | 2000-11-17 | 2002-05-29 | Best Quality B V | Device for treating a fluid-like sample, such as whole blood, with treatment fluid, use of such a device, and kit comprising such a device. |
EP1221340A1 (en) * | 2001-01-04 | 2002-07-10 | Heiko Dr. Schwertner | Method and modular device for detection or quantitative analysis of molecules and structures |
NO314206B1 (en) * | 2001-04-30 | 2003-02-10 | Erling Sundrehagen | Quantitative chemical analysis method, device / device, and application of said method and analysis set |
US7531362B2 (en) * | 2001-06-07 | 2009-05-12 | Medmira Inc. | Rapid diagnostic assay |
JP3931069B2 (en) | 2001-08-22 | 2007-06-13 | 協和メデックス株式会社 | Blood collection tool, quantitative solution preparation method using the same, quantitative solution preparation device and method of use thereof, and quantitative method using the quantitative solution |
JP4754746B2 (en) * | 2001-09-28 | 2011-08-24 | オリンパス株式会社 | Rod-shaped carrier and cylinder reaction vessel equipped with the same |
US7323144B2 (en) * | 2002-03-18 | 2008-01-29 | Leisure, Inc. | Apparatus for separating biological sample and separating method of the same |
AU2003220882A1 (en) * | 2002-03-29 | 2003-10-13 | Dainippon Pharmaceutical Co., Ltd. | Method of judging cardiotoxicity of anthracycline-type anticancer chemical therapeutic by detecting human h-fabp and reagent therefor |
US7108993B2 (en) | 2002-07-19 | 2006-09-19 | Bayer Healthcare Llc | Use of dual conjugated labels in the elimination of serum interference in immunochromatographic assays |
US6794877B2 (en) * | 2002-07-31 | 2004-09-21 | International Technidyne Corporation | Apparatus and method for analytical determinations |
GB2392854A (en) * | 2002-09-14 | 2004-03-17 | Secr Defence | Apparatus for isolating a filtrate from a sample |
JP4387166B2 (en) | 2002-11-19 | 2009-12-16 | 積水メディカル株式会社 | Filter device using plasma or serum separation membrane and plasma or serum separation method |
EP2711415B1 (en) * | 2002-12-26 | 2022-02-16 | Meso Scale Technologies, LLC. | Assay cartridges and methods of using the same |
DE10330981B4 (en) | 2003-07-09 | 2010-04-01 | Medion Diagnostics Ag | Apparatus and method for simultaneously performing blood grouping, serum cross-checking and antibody-screening |
CN1934445A (en) * | 2004-03-18 | 2007-03-21 | 富士胶片株式会社 | Analysis element used for inspection method of specimen |
US7378054B2 (en) * | 2004-04-16 | 2008-05-27 | Savvipharm Inc | Specimen collecting, processing and analytical assembly |
CA2507323A1 (en) * | 2005-05-13 | 2006-11-13 | Chromedx Inc. | Diagnostic whole blood and plasma apparatus |
WO2007002579A2 (en) * | 2005-06-23 | 2007-01-04 | Bioveris Corporation | Assay cartridges and methods for point of care instruments |
CN1952664B (en) | 2005-08-26 | 2011-05-18 | 中国科学院上海生命科学研究院 | Application of surface fatty acid-binding protein E-FABP |
WO2007049286A1 (en) | 2005-10-27 | 2007-05-03 | Tata Memorial Centre | A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma |
ES2433377T3 (en) * | 2006-02-21 | 2013-12-10 | Nexus Dx, Inc. | Procedures and compositions for the detection of analytes |
US20100311186A1 (en) | 2006-07-28 | 2010-12-09 | Biosite Incorporated | Devices and methods for performing receptor binding assays using magnetic particles |
WO2009086203A2 (en) | 2007-12-27 | 2009-07-09 | Aethlon Medical, Inc. | Method and apparatus for increasing contaminant clearance rates during extracorporeal fluid treatment |
DE202010003751U1 (en) * | 2010-03-17 | 2011-07-26 | Zumtobel Lighting Gmbh | Luminaire for generating a variable indirect lighting |
-
2007
- 2007-02-09 NL NL1033365A patent/NL1033365C2/en not_active IP Right Cessation
-
2008
- 2008-02-08 JP JP2009549023A patent/JP2010518393A/en active Pending
- 2008-02-08 WO PCT/NL2008/050072 patent/WO2008097091A1/en active Application Filing
- 2008-02-08 EP EP08712598A patent/EP2122349A1/en not_active Ceased
- 2008-02-08 CN CN200880011537.0A patent/CN101663580B/en not_active Expired - Fee Related
- 2008-02-08 RU RU2009133785/15A patent/RU2462717C2/en not_active IP Right Cessation
- 2008-02-08 US US12/526,394 patent/US9993816B2/en not_active Expired - Fee Related
-
2018
- 2018-05-24 US US15/989,068 patent/US20180264463A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458020A (en) * | 1982-11-15 | 1984-07-03 | Quidel | Integrated single tube plunger immunoassay system having plural reagent chambers |
US5776563A (en) * | 1991-08-19 | 1998-07-07 | Abaxis, Inc. | Dried chemical compositions |
US5830352A (en) * | 1994-12-02 | 1998-11-03 | Bristol-Myers Squibb Company | Centrifuge reagent delivery system |
US20030108447A1 (en) * | 1997-09-16 | 2003-06-12 | Masayuki Yokoi | Blood test container and blood test method |
US6632681B1 (en) * | 2000-07-24 | 2003-10-14 | Ey Laboratories | Reagent delivery device and method of use |
US20040203083A1 (en) * | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
US9327284B2 (en) * | 2004-01-21 | 2016-05-03 | Orion Diagnostica Oy | Sampling and assay device |
US20060063180A1 (en) * | 2004-09-17 | 2006-03-23 | Yoshihiro Yamashita | Method of nucleic acid isolation |
US9993816B2 (en) * | 2007-02-09 | 2018-06-12 | Fabpulous B.V. | Apparatus and method for separating and analyzing blood |
US9182417B2 (en) * | 2008-05-14 | 2015-11-10 | Fabpulous B.V. | Device and method for separating and analyzing blood |
US20160103134A1 (en) * | 2008-05-14 | 2016-04-14 | Fabpulous B.V. | Device and method for separating and analyzing blood |
Also Published As
Publication number | Publication date |
---|---|
CN101663580A (en) | 2010-03-03 |
RU2009133785A (en) | 2011-03-20 |
EP2122349A1 (en) | 2009-11-25 |
NL1033365C2 (en) | 2008-08-12 |
US9993816B2 (en) | 2018-06-12 |
RU2462717C2 (en) | 2012-09-27 |
WO2008097091A1 (en) | 2008-08-14 |
JP2010518393A (en) | 2010-05-27 |
WO2008097091B1 (en) | 2008-11-06 |
CN101663580B (en) | 2014-07-30 |
US20110008908A1 (en) | 2011-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180264463A1 (en) | Apparatus and method for separating and analyzing blood | |
AU2005236435B2 (en) | Specimen collecting, processing and analytical assembly | |
US6241689B1 (en) | Diagnostic test apparatus | |
CN107199061A (en) | A kind of multitask full-automatic biochemical detection chip | |
JP2011502623A (en) | Transdermal body fluid sampling and pretreatment apparatus and method | |
JPH07506256A (en) | Microfabricated sperm handling device | |
JP6513084B2 (en) | Device and method for sampling biological fluid and dispensing biological fluid using capillary tubes, and biological analysis instrument | |
WO1996041153A1 (en) | Biological cell sample holder for use in infrared and/or raman spectroscopy analysis | |
CN215506821U (en) | Whole blood separation micro-fluidic chip | |
US10830759B2 (en) | Arrangement for collection and separation of a body fluid for purposes of analysis and a method relating thereto | |
JP2001324500A (en) | Body fluid filtering unit and body fluid filtering device | |
JP2006501460A (en) | Sample collection device | |
KR102259432B1 (en) | Multi-system for conducting biochemistry and Blood test, and Multi-Disc therefor | |
US11280712B2 (en) | Transfer vessel and methods for reducing sample loss | |
EP3742174A1 (en) | Multi-system for simultaneously performing biochemical test and blood test, and multi-disc used therefor | |
US20130029318A1 (en) | Microchips and Methods for Testing a Fluid Sample | |
ITRM980313A1 (en) | MULTIPURPOSE TEST PLATE FOR ANALYSIS, PARTICULARLY FOR THE DIRECT ANALYSIS OF INTERNAL BLOOD OR FLUIDS CONTAINING PARTICLES OR | |
RU177742U1 (en) | Cartridge for determining hemostasis in human blood | |
US20190145966A1 (en) | Membrane-based analytical device for bodily fluids | |
JP2022525096A (en) | Hemolysis detection blood test device | |
MXPA98003814A (en) | Diagnost test system | |
JPS6276461A (en) | Method for inspecting blood component and sample for said inspection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |